Evidence map›Paper›PMID 27270324›Full record

ArticleOncotarget2016

Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway.

Fengkai Xu, Cheng-Zhi Xu, Jie Gu, Xiaoming Liu, Ronghua Liu, Enyu Huang, Yunfeng Yuan, Guangyin Zhao, Jiahao Jiang, Chen Xu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. [The study on effect of EIF3B in laryngeal carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025
    Article
  2. Article
  3. Article
  4. The Role of mCancers · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fengkai XuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Cheng-Zhi XuDepartment of Otolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Jie GuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Xiaoming LiuDepartment of Immunology and Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Ronghua LiuDepartment of Immunology and Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Enyu HuangDepartment of Immunology and Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Yunfeng YuanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Guangyin ZhaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Jiahao JiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Yiwei ChuDepartment of Immunology and Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai, P. R. China.
Chunlai LuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Di GeDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEsophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Eukaryotic translation initiation factors 3B (EIF3B) is considered to influence tumor proliferation, invasion, apoptosis and cell cycle, which act together to promote the progression of tumors. However, the role of EIF3B in ESCC is unknown. This study aims to explore the clinical and biological role of EIF3B in ESCC.

resultsEIF3B expressions were up-regulated in both ESCC tissues and cell lines. Overexpression of EIF3B was associated with tumor depth, lymph node metastasis and advanced TNM stage. Importantly, patients with high EIF3B expression suffered shorter overall and disease-free survival. Knockdown of EIF3B could inhibit cell proliferation and invasion, promote cell apoptosis, and interfere the cell cycle in vitro. EIF3B-knockdown cells could form smaller subcutaneous tumors in vivo. Finally, we demonstrated EIF3B could activate β-catenin signaling pathway.

methodsImmunohistochemical staining and Western blot were performed to detect the EIF3B expression in ESCC patient tissues and cell lines. The association between EIF3B expression and patients' prognosis was analyzed by Kaplan-Meier and Cox regression. Then, CCK-8, colony-formation, Transwell and wound-healing assay were performed to compare the bio-functional change after knockdown of EIF3B. Flow cytometry was applied to analyze the change of cell apoptosis and cycle induced by EIF3B knockdown. Tumor xenograft assay was done to verify the in-vitro results.

conclusionsEIF3B might serve as a novel marker for predicting prognosis of ESCC patients and as a potential therapeutic target, individually or together with other subunits of EIF3 complex.

Indexed as

Apoptosisbeta CateninBiomarkers, TumorCarcinoma, Squamous CellCell CycleCell Line, TumorCell MovementCell ProliferationDisease-Free SurvivalDisease ProgressionEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyEukaryotic Initiation Factor-3FemaleFollow-Up Studiesbeta CateninBiomarkers, TumorCTNNB1 protein, humanEIF3B protein, humanEukaryotic Initiation Factor-3RNA, Small Interferingesophageal squamous cell carcinomaeukaryotic translation initiation factors 3Bβ-catenin signaling pathway

Identifiers

PMID27270324
PMCPMC5190032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.